OncoHost

03/24/2026

🏆We’re proud to share that OncoHost has been named a winner in the 2026 Artificial Intelligence Excellence Awards by the Business Intelligence Group, taking top recognition in the Health category!

This award underscores what truly matters: real-world impact.

With PROphet®, our machine learning–based proteomics platform, we enable oncologists to make more precise, data-driven treatment decisions by decoding the patient’s systemic response—translating AI from promise into real-world clinical impact. 🚀

We’re grateful to the Business Intelligence Group for this recognition, and even more so to the teams across OncoHost who continue to push the boundaries of what’s possible in precision oncology.

https://prn.to/4d2Qfxe

/PRNewswire/ -- OncoHost, an AI-driven precision oncology company transforming clinical decision-making through proteomic analysis and machine learning, today...

03/23/2026

🚀 Redefining Precision Oncology with PROphet®
At OncoHost, we're not just keeping pace with innovation — we're setting the standard. The PROphet® platform is our flagship host-response profiling technology, designed to help oncologists make smarter, faster, and more personalized treatment decisions.

By analyzing proteomic patterns in patients' blood, PROphet® predicts therapeutic outcomes with unprecedented accuracy — giving physicians a powerful edge in managing complex cancers.

✅ Actionable insights
✅ AI-powered predictions
✅ Personalized patient care

The future of oncology isn’t just personalized. It’s precisely guided.
Learn more about how PROphet® is changing the game 👉

Explore OncoHost's home for cutting-edge precision oncology solutions, driving advancements in cancer care and personalized treatment strategies.

03/12/2026

Thank you MedPath for highlighting our latest research and covering this important milestone in proteomic biomarker science!

Our recently published study in the Journal of Pharmaceutical and Biomedical Analysis (JPBA) introduces a validated computational framework that harmonizes serum and plasma proteomic datasets - helping overcome a long-standing barrier in biomarker research.

By enabling reliable integration of these specimen types, this work expands the potential of existing datasets and supports more scalable, multi-cohort validation for precision oncology.

Appreciate the coverage and continued interest in advancing proteomics-driven precision oncology.
https://bit.ly/4s4SoNn

- OncoHost published a landmark study in JPBA introducing a validated computational framework that harmonizes serum and plasma proteomic datasets, overcoming a long-standing analytical barrier in biomarker research. - The multi-institutional study analyzed 7,289 proteins across 177 matched serum-pla...

03/09/2026

Have you read the latest peer-reviewed review on emerging predictive biomarkers for immunotherapy sensitivity in ?

The recently published article in ImmunoTargets and Therapy explores next-generation approaches that may help guide immunotherapy decision-making — and highlights PROphet® among the technologies contributing to this evolving landscape.

📖 Read the full review: Scan the QR code below or access the article here:
👉 https://bit.ly/4rW4cS5

02/25/2026

PROphet® is featured in a recent peer-reviewed review spotlighting next-generation predictive biomarkers shaping immunotherapy decision-making in !

📖 Read the full review: Scan the QR code below or click the link to explore the review in ImmunoTargets and Therapy:
👉 https://www.dovepress.com/emerging-predictive-biomarkers-of-immunotherapy-sensitivity-in-patient-peer-reviewed-fulltext-article-ITT

02/23/2026

We’re proud to share that PROphet® has been recognized in the latest peer-reviewed review on emerging predictive biomarkers of immunotherapy sensitivity in patients with NSCLC published by Dove Medical Press !
This comprehensive scientific article highlights cutting-edge approaches that are shaping personalized immunotherapy decision-making — and PROphet® is part of that conversation.

📖 Read the full review: Scan the QR code below or click the link to explore the review in ImmunoTargets and Therapy:
👉 https://www.dovepress.com/emerging-predictive-biomarkers-of-immunotherapy-sensitivity-in-patient-peer-reviewed-fulltext-article-ITT

02/18/2026

We are proud to announce the publication of our latest study in the Journal of Pharmaceutical and Biomedical Analysis (JPBA):
“Bridging the Gap: A Systematic Approach to Integrating Serum and Plasma Proteomic Datasets for Biomarker Studies.”

Our newly published work introduces a validated computational framework that harmonizes serum and plasma proteomic data, enabling systematic transformation between specimen types.
Importantly, we validated this bridging methodology using our AI-powered PROphet® platform. When applied to scaled serum data, the model maintained predictive accuracy, preserving clinical benefit classification and survival stratification in .

This milestone expands analytical flexibility, unlocks previously siloed datasets, and supports scalable multi-cohort validation - critical capabilities as proteomics becomes increasingly central to precision oncology.

We are grateful to our collaborators at the National Cancer Institute (NCI), Yale School of Medicine , Heidelberg University Hospital , and ions.bio for their partnership in advancing the field.

Read the news release here: https://tinyurl.com/ks3ww6hb
Read the full study here: https://doi.org/10.1016/j.jpba.2026.117421

/PRNewswire/ -- OncoHost, a technology company transforming precision oncology through proteomics and AI, today announced the publication of a new study in the...

02/17/2026

Industry News: FDA January 2026 - Key Highlights

January brought strong regulatory momentum in mutation-driven NSCLC:

🔬 Sevabertinib received Breakthrough Therapy Designation for 1L HER2-mutant NSCLC — expanding targeted options for a historically underserved subset.

🧬 Zoldonrasib earned Breakthrough status in KRAS G12D–mutant NSCLC post–PD-1/PD-L1 and platinum therapy — another step forward in cracking the RAS code.

🧪 Gotistobart secured Orphan Drug Designation for squamous NSCLC, signaling continued focus on high-unmet-need populations.

Precision isn’t the future — it’s the standard taking shape now.

Read more here: https://bit.ly/4c3rMYh

January 2026 marks a pivotal month in oncology, with the FDA advancing numerous innovative therapies for challenging cancers, emphasizing precision medicine.

02/16/2026

📄🧬PROphet is being recognized in a peer-reviewed biomarker landscape for metastatic !

A recently published review in Lung Cancer: Targets and Therapy highlights blood-based predictors of immune checkpoint inhibitor (ICI) response - and specifically calls out PROphet as a multi-analyte platform with clinical planning value.

Read the full review here: https://bit.ly/4pUlddQ

This link will take you to a page that’s not on LinkedIn

02/13/2026

February is National Cancer Prevention Month, a time to raise awareness about the steps we can all take to reduce cancer risk and prioritize our health.

Early detection and prevention are crucial in the fight against cancer. This month, let’s empower ourselves and our loved ones with the information and resources needed to make informed decisions about our health.

At OncoHost, we are committed to transforming cancer care through personalized treatment insights and cutting-edge research. Together, we can create a future with better outcomes and improved quality of life for cancer patients.

02/11/2026

🌍🔬 Celebrating Women & Girls in Science! 👩‍🔬💡

Today, on International Day of Women and Girls in Science, we honor the brilliant minds driving innovation in oncology and beyond. From groundbreaking research to transformative patient care, women continue to push the boundaries of cancer care and shape the future of medicine every day.

At OncoHost, we are incredibly proud of the talented women on our team who are making a profound impact in precision oncology. Your dedication, expertise, and passion are driving advancements in cancer research and helping improve patient outcomes worldwide.

02/10/2026

Every patient deserves a tailored approach—because in the fight against cancer, time is everything.

With OncoHost's cutting-edge PROphet® technology, we deliver actionable insights before treatment begins, helping clinicians make the best possible decisions from day one.

Because starting right makes all the difference.
Read more about PROphet® here: https://bit.ly/4cgNODS

Explore OncoHost's PROphet Technology, a cutting-edge precision oncology platform driving advancements in biomarkers for cancer treatment decisions.